The Lancet Rheumatology in conversation with

Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy


Listen Later

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

...more
View all episodesView all episodes
Download on the App Store

The Lancet Rheumatology in conversation withBy The Lancet Group


More shows like The Lancet Rheumatology in conversation with

View all
Rheumnow Podcast by Dr. Cush

Rheumnow Podcast

131 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,148 Listeners

The Evidence Based Rheumatology Podcast by Michael Putman

The Evidence Based Rheumatology Podcast

116 Listeners

ACR on Air by American College of Rheumatology

ACR on Air

67 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

21 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Oncology in conversation with by The Lancet Group

The Lancet Oncology in conversation with

1 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

2 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group

The Lancet Gastroenterology & Hepatology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

ACR Journals On Air by American College of Rheumatology

ACR Journals On Air

19 Listeners

The Lancet Regional Health in conversation with by The Lancet Group

The Lancet Regional Health in conversation with

0 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners